JP2005336206A - 組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 - Google Patents
組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 Download PDFInfo
- Publication number
- JP2005336206A JP2005336206A JP2005232394A JP2005232394A JP2005336206A JP 2005336206 A JP2005336206 A JP 2005336206A JP 2005232394 A JP2005232394 A JP 2005232394A JP 2005232394 A JP2005232394 A JP 2005232394A JP 2005336206 A JP2005336206 A JP 2005336206A
- Authority
- JP
- Japan
- Prior art keywords
- fipv
- virus
- feline
- vaccine
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711475 Feline infectious peritonitis virus Species 0.000 title claims abstract description 90
- 229960005486 vaccine Drugs 0.000 title claims abstract description 34
- 201000010099 disease Diseases 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 241000700638 Raccoonpox virus Species 0.000 title claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 51
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims description 22
- 101710141454 Nucleoprotein Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 241000282324 Felis Species 0.000 claims description 9
- 101710085938 Matrix protein Proteins 0.000 claims description 6
- 101710127721 Membrane protein Proteins 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 241000282330 Procyon lotor Species 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 241001647378 Chlamydia psittaci Species 0.000 claims description 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 2
- 241000714201 Feline calicivirus Species 0.000 claims description 2
- 241000714165 Feline leukemia virus Species 0.000 claims description 2
- 241000893980 Microsporum canis Species 0.000 claims description 2
- 206010051497 Rhinotracheitis Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000002613 Feline Panleukopenia Diseases 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 241000282326 Felis catus Species 0.000 abstract description 25
- 210000004027 cell Anatomy 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 21
- 239000013592 cell lysate Substances 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 210000003501 vero cell Anatomy 0.000 description 11
- 239000007758 minimum essential medium Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 101150029662 E1 gene Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000020030 perry Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 229950004398 broxuridine Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- SSSROGPPPVTHLX-FXQIFTODSA-N Ala-Arg-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSROGPPPVTHLX-FXQIFTODSA-N 0.000 description 1
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 1
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 1
- SHYYAQLDNVHPFT-DLOVCJGASA-N Ala-Asn-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SHYYAQLDNVHPFT-DLOVCJGASA-N 0.000 description 1
- MBWYUTNBYSSUIQ-HERUPUMHSA-N Ala-Asn-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N MBWYUTNBYSSUIQ-HERUPUMHSA-N 0.000 description 1
- NWVVKQZOVSTDBQ-CIUDSAMLSA-N Ala-Glu-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NWVVKQZOVSTDBQ-CIUDSAMLSA-N 0.000 description 1
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- IAUSCRHURCZUJP-CIUDSAMLSA-N Ala-Lys-Cys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CS)C(O)=O IAUSCRHURCZUJP-CIUDSAMLSA-N 0.000 description 1
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 1
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 1
- XAXMJQUMRJAFCH-CQDKDKBSSA-N Ala-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 XAXMJQUMRJAFCH-CQDKDKBSSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 1
- MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 1
- USNSOPDIZILSJP-FXQIFTODSA-N Arg-Asn-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O USNSOPDIZILSJP-FXQIFTODSA-N 0.000 description 1
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 1
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 1
- LLUGJARLJCGLAR-CYDGBPFRSA-N Arg-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LLUGJARLJCGLAR-CYDGBPFRSA-N 0.000 description 1
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 1
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 1
- AMIQZQAAYGYKOP-FXQIFTODSA-N Arg-Ser-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O AMIQZQAAYGYKOP-FXQIFTODSA-N 0.000 description 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 1
- VRTWYUYCJGNFES-CIUDSAMLSA-N Arg-Ser-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O VRTWYUYCJGNFES-CIUDSAMLSA-N 0.000 description 1
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 1
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 1
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 description 1
- CIBWFJFMOBIFTE-CIUDSAMLSA-N Asn-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N CIBWFJFMOBIFTE-CIUDSAMLSA-N 0.000 description 1
- POOCJCRBHHMAOS-FXQIFTODSA-N Asn-Arg-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O POOCJCRBHHMAOS-FXQIFTODSA-N 0.000 description 1
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 1
- RCENDENBBJFJHZ-ACZMJKKPSA-N Asn-Asn-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCENDENBBJFJHZ-ACZMJKKPSA-N 0.000 description 1
- ZWASIOHRQWRWAS-UGYAYLCHSA-N Asn-Asp-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZWASIOHRQWRWAS-UGYAYLCHSA-N 0.000 description 1
- UHGUKCOQUNPSKK-CIUDSAMLSA-N Asn-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N UHGUKCOQUNPSKK-CIUDSAMLSA-N 0.000 description 1
- GIQCDTKOIPUDSG-GARJFASQSA-N Asn-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N)C(=O)O GIQCDTKOIPUDSG-GARJFASQSA-N 0.000 description 1
- YXVAESUIQFDBHN-SRVKXCTJSA-N Asn-Phe-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O YXVAESUIQFDBHN-SRVKXCTJSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 1
- BFOYULZBKYOKAN-OLHMAJIHSA-N Asp-Asp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFOYULZBKYOKAN-OLHMAJIHSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- SFJUYBCDQBAYAJ-YDHLFZDLSA-N Asp-Val-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SFJUYBCDQBAYAJ-YDHLFZDLSA-N 0.000 description 1
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- QQAYIVHVRFJICE-AEJSXWLSSA-N Cys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N QQAYIVHVRFJICE-AEJSXWLSSA-N 0.000 description 1
- WVWRADGCZPIJJR-IHRRRGAJSA-N Cys-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CS)N WVWRADGCZPIJJR-IHRRRGAJSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701915 Feline panleukopenia virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- KWUSGAIFNHQCBY-DCAQKATOSA-N Gln-Arg-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O KWUSGAIFNHQCBY-DCAQKATOSA-N 0.000 description 1
- VVWWRZZMPSPVQU-KBIXCLLPSA-N Gln-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N VVWWRZZMPSPVQU-KBIXCLLPSA-N 0.000 description 1
- AJDMYLOISOCHHC-YVNDNENWSA-N Gln-Gln-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AJDMYLOISOCHHC-YVNDNENWSA-N 0.000 description 1
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 1
- JXBZEDIQFFCHPZ-PEFMBERDSA-N Gln-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JXBZEDIQFFCHPZ-PEFMBERDSA-N 0.000 description 1
- HSHCEAUPUPJPTE-JYJNAYRXSA-N Gln-Leu-Tyr Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HSHCEAUPUPJPTE-JYJNAYRXSA-N 0.000 description 1
- HHRAEXBUNGTOGZ-IHRRRGAJSA-N Gln-Phe-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O HHRAEXBUNGTOGZ-IHRRRGAJSA-N 0.000 description 1
- XZUUUKNKNWVPHQ-JYJNAYRXSA-N Gln-Phe-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O XZUUUKNKNWVPHQ-JYJNAYRXSA-N 0.000 description 1
- XIYWAJQIWLXXAF-XKBZYTNZSA-N Gln-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O XIYWAJQIWLXXAF-XKBZYTNZSA-N 0.000 description 1
- PXHABOCPJVTGEK-BQBZGAKWSA-N Glu-Gln-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O PXHABOCPJVTGEK-BQBZGAKWSA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- BIYNPVYAZOUVFQ-CIUDSAMLSA-N Glu-Pro-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O BIYNPVYAZOUVFQ-CIUDSAMLSA-N 0.000 description 1
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 1
- QGAJQIGFFIQJJK-IHRRRGAJSA-N Glu-Tyr-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O QGAJQIGFFIQJJK-IHRRRGAJSA-N 0.000 description 1
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 1
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 1
- XEJTYSCIXKYSHR-WDSKDSINSA-N Gly-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN XEJTYSCIXKYSHR-WDSKDSINSA-N 0.000 description 1
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 1
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 1
- JYGYNWYVKXENNE-OALUTQOASA-N Gly-Tyr-Trp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JYGYNWYVKXENNE-OALUTQOASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- KZTLOHBDLMIFSH-XVYDVKMFSA-N His-Ala-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O KZTLOHBDLMIFSH-XVYDVKMFSA-N 0.000 description 1
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 1
- WYSJPCTWSBJFCO-AVGNSLFASA-N His-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CN=CN1)N WYSJPCTWSBJFCO-AVGNSLFASA-N 0.000 description 1
- YAJQKIBLYPFAET-NAZCDGGXSA-N His-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N)O YAJQKIBLYPFAET-NAZCDGGXSA-N 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 1
- CWJQMCPYXNVMBS-STECZYCISA-N Ile-Arg-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N CWJQMCPYXNVMBS-STECZYCISA-N 0.000 description 1
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- IXEFKXAGHRQFAF-HVTMNAMFSA-N Ile-Glu-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N IXEFKXAGHRQFAF-HVTMNAMFSA-N 0.000 description 1
- WIZPFZKOFZXDQG-HTFCKZLJSA-N Ile-Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O WIZPFZKOFZXDQG-HTFCKZLJSA-N 0.000 description 1
- GAZGFPOZOLEYAJ-YTFOTSKYSA-N Ile-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N GAZGFPOZOLEYAJ-YTFOTSKYSA-N 0.000 description 1
- VLCMCYDZJCWPQT-VKOGCVSHSA-N Ile-Met-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N VLCMCYDZJCWPQT-VKOGCVSHSA-N 0.000 description 1
- OTSVBELRDMSPKY-PCBIJLKTSA-N Ile-Phe-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OTSVBELRDMSPKY-PCBIJLKTSA-N 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- KBDIBHQICWDGDL-PPCPHDFISA-N Ile-Thr-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N KBDIBHQICWDGDL-PPCPHDFISA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- QSXSHZIRKTUXNG-STECZYCISA-N Ile-Val-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QSXSHZIRKTUXNG-STECZYCISA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KVRKAGGMEWNURO-CIUDSAMLSA-N Leu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N KVRKAGGMEWNURO-CIUDSAMLSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 description 1
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 1
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 1
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- HIIZIQUUHIXUJY-GUBZILKMSA-N Lys-Asp-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HIIZIQUUHIXUJY-GUBZILKMSA-N 0.000 description 1
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 1
- WTZUSCUIVPVCRH-SRVKXCTJSA-N Lys-Gln-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WTZUSCUIVPVCRH-SRVKXCTJSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- VSTNAUBHKQPVJX-IHRRRGAJSA-N Lys-Met-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O VSTNAUBHKQPVJX-IHRRRGAJSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- GAELMDJMQDUDLJ-BQBZGAKWSA-N Met-Ala-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O GAELMDJMQDUDLJ-BQBZGAKWSA-N 0.000 description 1
- HUKLXYYPZWPXCC-KZVJFYERSA-N Met-Ala-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HUKLXYYPZWPXCC-KZVJFYERSA-N 0.000 description 1
- HLYIDXAXQIJYIG-CIUDSAMLSA-N Met-Gln-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HLYIDXAXQIJYIG-CIUDSAMLSA-N 0.000 description 1
- AOFZWWDTTJLHOU-ULQDDVLXSA-N Met-Lys-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AOFZWWDTTJLHOU-ULQDDVLXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- -1 NZ-amine Chemical class 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- BBDSZDHUCPSYAC-QEJZJMRPSA-N Phe-Ala-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BBDSZDHUCPSYAC-QEJZJMRPSA-N 0.000 description 1
- CSYVXYQDIVCQNU-QWRGUYRKSA-N Phe-Asp-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O CSYVXYQDIVCQNU-QWRGUYRKSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 1
- BYAIIACBWBOJCU-URLPEUOOSA-N Phe-Ile-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BYAIIACBWBOJCU-URLPEUOOSA-N 0.000 description 1
- BTAIJUBAGLVFKQ-BVSLBCMMSA-N Phe-Trp-Val Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=CC=C1 BTAIJUBAGLVFKQ-BVSLBCMMSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- AUQGUYPHJSMAKI-CYDGBPFRSA-N Pro-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 AUQGUYPHJSMAKI-CYDGBPFRSA-N 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- SXMSEHDMNIUTSP-DCAQKATOSA-N Pro-Lys-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SXMSEHDMNIUTSP-DCAQKATOSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- UICKAKRRRBTILH-GUBZILKMSA-N Ser-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N UICKAKRRRBTILH-GUBZILKMSA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 1
- WGDYNRCOQRERLZ-KKUMJFAQSA-N Ser-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N WGDYNRCOQRERLZ-KKUMJFAQSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 1
- FVFUOQIYDPAIJR-XIRDDKMYSA-N Ser-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FVFUOQIYDPAIJR-XIRDDKMYSA-N 0.000 description 1
- TYIHBQYLIPJSIV-NYVOZVTQSA-N Ser-Trp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)[C@H](CO)N TYIHBQYLIPJSIV-NYVOZVTQSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
- YSXYEJWDHBCTDJ-DVJZZOLTSA-N Thr-Gly-Trp Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O YSXYEJWDHBCTDJ-DVJZZOLTSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- MEBDIIKMUUNBSB-RPTUDFQQSA-N Thr-Phe-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MEBDIIKMUUNBSB-RPTUDFQQSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- BEWOXKJJMBKRQL-AAEUAGOBSA-N Trp-Gly-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N BEWOXKJJMBKRQL-AAEUAGOBSA-N 0.000 description 1
- RXEQOXHCHQJMSO-IHPCNDPISA-N Trp-His-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O RXEQOXHCHQJMSO-IHPCNDPISA-N 0.000 description 1
- ABEVJDLMFPTGPS-SZMVWBNQSA-N Trp-Met-Met Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(O)=O ABEVJDLMFPTGPS-SZMVWBNQSA-N 0.000 description 1
- BOMYCJXTWRMKJA-RNXOBYDBSA-N Trp-Phe-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N BOMYCJXTWRMKJA-RNXOBYDBSA-N 0.000 description 1
- SUEGAFMNTXXNLR-WFBYXXMGSA-N Trp-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O SUEGAFMNTXXNLR-WFBYXXMGSA-N 0.000 description 1
- HIZDHWHVOLUGOX-BPUTZDHNSA-N Trp-Ser-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O HIZDHWHVOLUGOX-BPUTZDHNSA-N 0.000 description 1
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 1
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 1
- PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 description 1
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- FGVFBDZSGQTYQX-UFYCRDLUSA-N Tyr-Phe-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O FGVFBDZSGQTYQX-UFYCRDLUSA-N 0.000 description 1
- ARMNWLJYHCOSHE-KKUMJFAQSA-N Tyr-Pro-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O ARMNWLJYHCOSHE-KKUMJFAQSA-N 0.000 description 1
- SMUWZUSWMWVOSL-JYJNAYRXSA-N Tyr-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N SMUWZUSWMWVOSL-JYJNAYRXSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- UEOOXDLMQZBPFR-ZKWXMUAHSA-N Val-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N UEOOXDLMQZBPFR-ZKWXMUAHSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 1
- MHAHQDBEIDPFQS-NHCYSSNCSA-N Val-Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C MHAHQDBEIDPFQS-NHCYSSNCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 1
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 1
- RSGHLMMKXJGCMK-JYJNAYRXSA-N Val-Met-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N RSGHLMMKXJGCMK-JYJNAYRXSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000010717 cat disease Diseases 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000013404 process transfer Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/819—Viral vaccine for feline species, e.g. cats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
【解決手段】 FIPV NまたはM/E1タンパクに対する遺伝子を有するRRPVと、医薬上許容される担体およびアジュバントからなるワクチン、ならびにこのワクチンをネコに投与することからなるFIPVに起因する疾患の予防方法が提供される。
【選択図】 なし
Description
本発明は、ネコ伝染性腹膜炎ウイルス(FIPV)のヌクレオカプシド(N)およびトランスメンブレン(M/E1)タンパクを発現する組換えアライグマポックスウイルス(RRPV)をワクチンとして用いた、FIPVに起因する疾患の予防に関する。
ネコ伝染性腹膜炎ウイルス(FIPV)は、ネコにおける全身性感染を誘発するが、この感染は致命的であることが多い。この疾患の滲出型は、線維素性の腹水の蓄積によって特徴付けられる。この疾患の非滲出型は、肝臓、脾臓、腎臓、肺および腸を含む(しかし、これらに限定されない)多数の臓器における肉芽腫性病変によって特徴付けられる。その総説としては、シー・イー・グリーン(C.E.Greene)編集のインフェクシャス・ディシージズ・オブ・ザ・ドッグ・アンド・キャッツ(Infectious Diseases of the Dog and Cats)(ダブリュー・ビー・ソーンダーズ・カンパニー(W.B.Saunders Co.)、フィラデルフィア、PA、1990年)におけるバーロウ,ジェイ・イー(Barlough,J.E.)およびシ−・エイ・ストッダルト(C.A.Stoddart)のフィーライン・コロナヴァイラル・インフェクションズ(Feline Coronaviral Infections),300-312頁を参照されたい。
本発明は、FIPVに対するネコの防御免疫の誘発に関する。本発明のある目的は、FIPVのNまたはM/E1タンパクに対する遺伝子を含む組換えアライグマポックスウイルス(各々、RRPV-NおよびRRPV-E1)を提供することである。すなわち、本発明のRRPVは、FIPVのNおよびM/E1タンパクからなる群から選択される要素をコードするDNA配列からなる少なくとも1つの内部遺伝子を有する。
以下の実施例によって、本発明をさらに詳しく説明するが、本発明の範囲はこれら実施例に限定されるものではない。細胞を感染させ、かつ、トランスフェクトさせ、ウイルスをプラーク精製し、イムノブロット分析を行うのに用いた手法は、当該技術分野で広く実施されている。
1.FIPV NおよびE1遺伝子のクローニングならびにトランスファープラスミドの調製
本発明で用いたE1およびN遺伝子のヌクレオチド配列およびアミノ酸配列を、各々、図1〜2と配列表の配列番号:1および図3〜5と配列表の配列番号:2に示す。FIPV NおよびE1遺伝子をクローニングし、それらをpSC11トランスファーベクターに挿入する方法は、欧州特許出願第0,376,744号に詳述されている。E1およびN遺伝子に対するcDNAをクローン化するのに用いたプラスミドを図6に示す。pUC18:E1-Nは、共に連結したFIPV E1およびN遺伝子を含有する1.9kbpEcoR1-Sph1フラグメントを有する。E1およびN遺伝子を有するpSC11プラスミドを、各々、図7および図8に示す。これらプラスミドのヌクレオチド配列を図9〜11と配列表の配列番号3および図12〜14と配列表の配列番号:4に示す。
80%集密的(約5×106個の細胞/100mm組織培養皿)なVero細胞(ATCC CCL81)の単層を、37℃で30〜60分間、野性型アライグマポックスウイルス(ATCC VR-838)に、0.1TCID50/細胞の感染多重度(MOI)で感染させた。培地(2ml)は、0.05%ラクトアルブミン加水分解産物および15μg/mlゲンタマイシン硫酸塩を含有するイーグル最小必須培地(「MEM」、ギブコ(Gibco)BRL#410-1500)からなり、重炭酸ナトリウムでpH7.2に調節した。感染後、培地を取り出し、製造業者の説明書に従って、各々、トランスフェクタム(Transfectam@;プロメガ・コーポレーション(Promega Corporation)、マジソン、WI)およびDOTAP(ベーリンガー・マンハイム(Boehringer Mannheim)、インディアナポリス、IN)を用いたカチオン性リポソーム媒介トランスフェクションによって、細胞にpSC11-FIPV N、pSC11-FPIV E1、またはpSC11 N/E1トランスファープラスミドをトランスフェクトさせた。これら細胞を、5%ウシ胎児血清(FBS)を含有する3mlのMEM中で、DNA-リポソーム混合物と共に、(5%CO2下)37℃で一晩インキュベートした後、培地を8mlの新鮮なMEM-5%FBSと置換した。トランスフェクトした細胞を、細胞変性効果(CPE)を示すものが80%を越えるまで、(5%CO2下)37℃でインキュベートしたが、これには約3〜4日かかった。ウイルス-細胞溶解物を、次いで、プレートから取り出し、2サイクルの凍結-解凍に供してから、−70℃で保存した。
FIPV N遺伝子を有するRRPV(RRPV-FIPV N)を、標準的なウイルスプラーク精製方法によって、pSC11-FIPV N-Vero細胞トランスフェクションから単離・精製した。Vero細胞の単層(50〜80%集密的)を、ウイルス-細胞溶解物の10倍系列(10−1〜10−3)希釈液の2mlによって、37℃で1時間感染させた。インキュベートした後、培地を取り出し、感染した細胞に、MEM/5%FBSを含有する1.25%ノーブル(Noble)寒天培地8〜10mlを重ねた。感染した細胞を、次いで、(5%CO2下)37℃で3〜4日間インキュベートし、0.5×PBSおよび600μg/mlの5-ブロモ-4-クロロ-3-インドリル-β-D-ガラクトピラノシド(X-gal;ステイツ・バイオケミカル(States Biochemical)、クリーブランド、オハイオ州)を含有する1.25%ノーブル(Noble)寒天培地4mlを再び重ねた。これらプレートを、青色(すなわち、β-ガラクトシダーゼ陽性)のウイルスプラークが観察されるまで、(5%CO2下)37℃で4〜16時間インキュベートした。組換えウイルスプラークを、1ccの注射器に取り付けた先端の平坦な滅菌針を用いて採集し、0.25μg/mlトリプシンの0.5ml中に懸濁し、ボルテックスミキサーで激しく撹拌し、37℃で15〜30分間インキュベートした。次いで、破砕したウイルスプラークを25cm2のフラスコ中における5×105個のVero細胞上に接種し、80%を越えるCPEが観察されるまで、(5%CO2下)37℃でインキュベートした。RRPV-FIPV Nを含有するウイルス-細胞溶解物は、2サイクルの凍結-解凍に供し、−70℃で保存した。6つの個々のRRPV-FIPV Nクローンを選択し、上記のようにプラーク精製を5回行った。
RRPV-FIPV Nについて説明した方法を多少変更して用いて、FIPV E1遺伝子を有するRRPV(RRPV-FIPV E1)を単離し、pSC11-FIPV E1トランスフェクトVero細胞から精製した。この場合、最初のウイルス-細胞溶解物由来のチミジンキナーゼ欠損(tk-)RRPVを、tk-RAT-2細胞(ATCC CRL1764)上で選択した。これは、最初のウイルス-細胞溶解物の1mlを、MEM中に30μg/mlの5-ブロモデオキシウリジン(BrdU)の存在下、75cm2のフラスコ中におけるRAT-2細胞(約5×106個の細胞)の単層上に接種することによって実施した。感染した単層を、70%を越えるCPEが観察されるまで、(5%CO2下)37℃で3〜4日間インキュベートした。tk-ウイルス細胞溶解物を、2サイクルの凍結-解凍に供し、−70℃で保存した。2つの個々のRRPV-FIPV E1クローンを選択し、RRPV-FIPV Nについて上で説明したように、6サイクルのプラーク精製に供した。
RRPV中におけるFIPV NおよびE1の存在は、ポリメラーゼ連鎖反応(PCR)を用いて確認した。90μlのウイルス-細胞溶解物を10μlの10倍濃縮PCR溶解緩衝液(100mMトリス(Tris)-HCl緩衝液、pH8.5;500mM KCl;25mM MgCl2;5%ツウィーン(Tween)20;3mg/mlプロテイナーゼ(Proteinase)K)と共に、50℃で16時間インキュベートし、次いで10分間沸騰させた。この溶解物10μlをPCRに用いた。PCRは、10μlの10mMトリス(Tris)-HCl緩衝液,pH8.3;50mM KCl;200μMの各デオキシリボヌクレオチド三リン酸、1.5mM MgCl2;30ピコモルの各オリゴヌクレオチドプライマー;および、2.5単位のアンプリターク(AmpliTaq@)DNAポリメラーゼ(パーキン-エルマー・シータス(Perkin-Elmer Cetus)、ノルウォーク、CT)中で実施した。FIPV NのPCRに用いたプライマーは、各々、FIPV Nオープンリーディングフレームのヌクレオチド68〜91および721〜744に対応する以下のプライマー1および2である。
(2)5'-AGCACCATAGAAAGTTGTCACATC-3'
25cm2のフラスコ中におけるVero細胞の集密的単層(1〜2×106個の細胞)を、RRPV-FIPV NまたはRRPV-FIPV E1のいずれかのクローンに、0.1のMOIで感染させた。感染した細胞を、約80%の細胞が細胞変性効果を示すまで、(5%CO2下)37℃で2〜3日間インキュベートした。ウイルス-細胞溶解物を調製し、20μlの試料を5μlの5×ラエムリ(Laemmli)試料緩衝液(0.3Mトリス(Tris)-HCl緩衝液、pH6.8、5%SDS、50%グリセロール、0.4%ブロモフェノールブルー、および3%2-β-メルカプトエタノールを含有)に添加し、95℃で5分間加熱した。変性したタンパク試料を、前に説明したように、4〜15%勾配ポリアクリルアミドゲルを用いたSDS/ポリアクリルアミド電気泳動によって分離した。マニアチス(Maniatis)ら、モレキュラー・クローニング(Molecular Cloning):ア・ラボラトリー・マニュアル(A Laboratory Manual)、1982年、コールド・スプリング・ハーバー・プレス(Cold Spring Harbor Press)。電気泳動後、製造業者の説明書に従い、バイオ-ラッド(Bio-Rad)転写装置を用いた電気転写によって、タンパクをニトロセルロース(バイオ-ラッド・ラボラトリー(Bio-Rad Laboratories)、ハーキュリーズ、CA)に転写した。転写は、0.2Mグリシンおよび20%メタノールを含有する25mMトリス(Tris)-HCl緩衝液中、定電流電圧50Vで、45分間実施した。
ウイルスの10倍系列希釈物を、MEM中に調製し、96ウェルプレート中のVero細胞(各ウェルあたり1×104個の細胞)に、5通り接種した。ウイルス製剤は、等量の0.5%トリプシン中に希釈し、封入体からウイルスを放出させるために、37℃で30分間インキュベートすることによって調製すればよい。プレートを(5%CO2下)37℃で3〜5日間インキュベートし、アライグマポックスウイルスを象徴する細胞病理学について観察する。力価は、リード(Reed)およびミュンヒ(Muench)(ジ・アメリカン・ジャーナル・オブ・ハイジーン(The American Journal of Hygiene)27(3)巻:493-497頁、1938年)の方法を用いた細胞病理学に基づく50%終点として計算する。
ワクチンの調製およびネコにおける効力試験
1.RRPV-FIPV NおよびE1ウイルスのマスターシードの調製
各々の組換えウイルスの単一クローンを大規模な拡大(expansion)について選択し、マスターシードウイルスとした。選択の基準は、1)純度の検証:ポリメラーゼ連鎖反応を利用して、このクローンが野生型ウイルスで汚染されていないことを確かめた;および、2)ウェスタンブロットまたは他の抗原検出方法による適当な組換えタンパク発現の検証であった。
3×107個のVero細胞を、200mlの増殖培地(0.5%ラクトアルブミン加水分解産物および5%FBSを含有するMEM)を入れた850cm2回転ビン中に播種し、37℃で18時間インキュベートした。翌日、培地を細胞から除去し、感染培地(0.5%ラクトアルブミン加水分解産物および2.5%FBSを含有するMEM)中に0.01のMOIまで希釈した50mlのRRPV-FIPV Nウイルスで置換した。用いたウイルスは、マスターシード調製物から第2継代のものであった。ウイルスを、細胞に37℃で30分間吸収させた後、培地の容量を1本の回転ビンあたり150mlに調節した。これら回転ビンを、100%の細胞病理学が明らかになるまで(3日間)、37℃でインキュベートした。ウイルス-細胞溶解物を採集し、(−70℃で)凍結保存した。ウイルス力価は、106.97TCID50/mlであると測定された。
24匹(雄7匹および雌17匹)の月齢9カ月のネコ(特定の病原体を有しない、ハーラン・スプラーグ・ドーリー(Harlan Sprague Dawley)、マディソン、WI)を用いて、RRPV-FIPV Nワクチンの効力を実証した。以下に示すように、ネコを5つのグループに分割し、21日間隔でワクチン接種を2回行った。
第2のワクチン接種から2週間後、ネコに、103.4TCID50のネコ腸内コロナウイルス(79-1683株、ATCC VR-989)を経口的に接種した。このウイルスは、次のFIPV感染を増強することができる潜在的な感染を誘発する。3週間後、ネコに、103.4TCID50のFIPV(79-1146株、ATCC VR-990)を経口的に抗原投与(challenge)した。ネコを、発熱、黄疸、白血球減少、貧血、体重減少、食欲減退、抑うつ症、脱水症状、および腹腔膨化を含む臨床疾患の徴候について、抗原投与してから合計64週間にわたって毎週モニターした。瀕死状態のネコは、参加している獣医が安楽死させ、死後の病理学的検査を実施した。臨床上の疾患の徴候は、以下に示すように評価された。
毒性FIPVの接種によって、野生型アライグマポックスウイルスをワクチン接種した対照のネコの4/5(80%)において致死的な感染が誘発された(表1)。対照のネコにおいては、滲出型および非滲出型の両方の疾患が見られた。他方、皮下へのワクチン接種による抗原投与の後、臨床上の疾患は本質的に見られなかった。これらのネコにおける散発性の発熱は、興奮性に帰することができ、1264番のネコにおけるある日のわずかな貧血は有意な発見ではない。皮下へのワクチン接種は、対照のネコと比較した場合に、臨床上の徴候(p<0.05、共変分析(ANOVA)による)および死亡(p<0.01、χ二乗分析による)における統計的に有意な減少を示した。
本発明によれば、ネコ伝染性腹膜炎ウイルス(FIPV)のヌクレオカプシド(N)およびトランスメンブレン(M/E1)タンパクを発現する組換えアライグマポックスウイルス(RRPV)が得られる。この組換えウイルスは、単独または担体やアジュバントと組み合わせて、ワクチンとして有用であり、FIPVに起因する疾患を効果的に予防することができる。
配列番号:1
配列の長さ:789
配列の型:核酸
鎖の数:二本鎖
トポロジー:直鎖状
配列の種類:cDNA
起源
生物名:ネコ伝染性腹膜炎ウイルス
直接の起源
クローン名:FIPV E1
配列:
ATG AAG TAC ATT TTG CTA ATA CTC GCG TGC ATA ATT GCA TGC GTT TAT 48
Met Lys Tyr Ile Leu Leu Ile Leu Ala Cys Ile Ile Ala Cys Val Tyr
1 5 10 15
GGT GAA CGC TAC TGT GCC ATG CAA GAC AGT GGC TTG CAG TGT ATT AAT 96
Gly Glu Arg Tyr Cys Ala Met Gln Asp Ser Gly Leu Gln Cys Ile Asn
20 25 30
GGC ACA AAT TCA AGA TGT CAA ACC TGC TTT GAA CGT GGT GAT CTT ATT 144
Gly Thr Asn Ser Arg Cys Gln Thr Cys Phe Glu Arg Gly Asp Leu Ile
35 40 45
TGG CAT CTT GCT AAC TGG AAC TTC AGC TGG TCT GTA ATA TTG ATT GTT 192
Trp His Leu Ala Asn Trp Asn Phe Ser Trp Ser Val Ile Leu Ile Val
50 55 60
TTT ATA ACA GTG TTA CAA TAT GGC AGA CCA CAA TTT AGC TGG CTC GTT 240
Phe Ile Thr Val Leu Gln Tyr Gly Arg Pro Gln Phe Ser Trp Leu Val
65 70 75 80
TAT GGC ATT AAA ATG CTG ATC ATG TGG CTA TTA TGG CCT ATT GTT CTA 288
Tyr Gly Ile Lys Met Leu Ile Met Trp Leu Leu Trp Pro Ile Val Leu
85 90 95
GCG CTT ACG ATT TTT AAT GCA TAC TCT GAG TAC CAA GTT TCC AGA TAT 336
Ala Leu Thr Ile Phe Asn Ala Tyr Ser Glu Tyr Gln Val Ser Arg Tyr
100 105 110
GTA ATG TTC GGC TTT AGT GTT GCA GGT GCA GTT GTA ACG TTT GCA CTT 384
Val Met Phe Gly Phe Ser Val Ala Gly Ala Val Val Thr Phe Ala Leu
115 120 125
TGG ATG ATG TAT TTT GTG AGA TCT GTT CAG CTA TAT AGA AGA ACC AAA 432
Trp Met Met Tyr Phe Val Arg Ser Val Gln Leu Tyr Arg Arg Thr Lys
130 135 140
TCA TGG TGG TCT TTT AAT CCT GAG ACT AAT GCA ATT CTT TGT GTT AAT 480
Ser Trp Trp Ser Phe Asn Pro Glu Thr Asn Ala Ile Leu Cys Val Asn
145 150 155 160
GCA TTG GGT AGA AGT TAT GTG CTT CCC TTA GAT GGT ACT CCT ACA GGT 528
Ala Leu Gly Arg Ser Tyr Val Leu Pro Leu Asp Gly Thr Pro Thr Gly
165 170 175
GTT ACC CTT ACT CTA CTT TCA GGA AAT CTA TAT GCT GAA GGT TTC AAA 576
Val Thr Leu Thr Leu Leu Ser Gly Asn Leu Tyr Ala Glu Gly Phe Lys
180 185 190
ATG GCT GGT GGT TTA ACC ATC GAG CAT TTG CCT AAA TAC GTC ATG ATT 624
Met Ala Gly Gly Leu Thr Ile Glu His Leu Pro Lys Tyr Val Met Ile
195 200 205
GCT ACA CCT AGT AGA ACC ATC GTT TAT ACA TTA GTT GGA AAA CAA TTA 672
Ala Thr Pro Ser Arg Thr Ile Val Tyr Thr Leu Val Gly Lys Gln Leu
210 215 220
AAA GCA ACT ACT GCC ACA GGA TGG GCT TAC TAC GTA AAA TCT AAA GCT 720
Lys Ala Thr Thr Ala Thr Gly Trp Ala Tyr Tyr Val Lys Ser Lys Ala
225 230 235 240
GGT GAT TAC TCA ACA GAA GCA CGT ACT GAC AAT TTG AGT GAA CAT GAA 768
Gly Asp Tyr Ser Thr Glu Ala Arg Thr Asp Asn Leu Ser Glu His Glu
245 250 255
AAA TTA TTA CAT ATG GTG TAA 789
Lys Leu Leu His Met Val
260
配列の長さ:1134
配列の型:核酸
鎖の数:二本鎖
トポロジー:直鎖状
配列の種類:cDNA
起源
生物名:ネコ伝染性腹膜炎ウイルス
直接の起源
クローン名:FIPV N
配列:
ATG GCC ACA CAG GGA CAA CGC GTC AAC TGG GGA GAT GAA CCT TCC AAA 48
Met Ala Thr Gln Gly Gln Arg Val Asn Trp Gly Asp Glu Pro Ser Lys
1 5 10 15
AGA CGT GGT CGT TCT AAC TCT CGT GGT CGG AAG AAT AAT GAT ATA CCT 96
Arg Arg Gly Arg Ser Asn Ser Arg Gly Arg Lys Asn Asn Asp Ile Pro
20 25 30
TTG TCA TTC TAC AAC CCC ATT ACC CTC GAA CAA GGA TCT AAA TTT TGG 144
Leu Ser Phe Tyr Asn Pro Ile Thr Leu Glu Gln Gly Ser Lys Phe Trp
35 40 45
AAT TTA TGT CCG AGA GAC CTT GTT CCC AAA GGA ATA GGT AAT AAG GAT 192
Asn Leu Cys Pro Arg Asp Leu Val Pro Lys Gly Ile Gly Asn Lys Asp
50 55 60
CAA CAA ATT GGT TAT TGG AAT AGA CAG ATT CGT TAT CGT ATT GTA AAA 240
Gln Gln Ile Gly Tyr Trp Asn Arg Gln Ile Arg Tyr Arg Ile Val Lys
65 70 75 80
GGC CAG CGT AAG GAA CTC GCT GAG AGG TGG TTC TTT TAC TTC TTA GGT 288
Gly Gln Arg Lys Glu Leu Ala Glu Arg Trp Phe Phe Tyr Phe Leu Gly
85 90 95
ACA GGA CCT CAT GCT GAT GCT AAA TTC AAA GAC AAG ATT GAT GGA GTC 336
Thr Gly Pro His Ala Asp Ala Lys Phe Lys Asp Lys Ile Asp Gly Val
100 105 110
TTC TGG GTT GCA AGG GAT GGT GCC ATG AAC AAG CCC ACA ACG CTT GGC 384
Phe Trp Val Ala Arg Asp Gly Ala Met Asn Lys Pro Thr Thr Leu Gly
115 120 125
ACT CGT GGA ACC AAT AAC GAA TCC AAA CCA CTG AGA TTT GAT GGT AAG 432
Thr Arg Gly Thr Asn Asn Glu Ser Lys Pro Leu Arg Phe Asp Gly Lys
130 135 140
ATA CCG CCA CAG TTT CAG CTT GAA GTG AAC CGT TCT AGG AAC AAT TCA 480
Ile Pro Pro Gln Phe Gln Leu Glu Val Asn Arg Ser Arg Asn Asn Ser
145 150 155 160
AGG TCT GGT TCT CAG TCT AGA TCT GTT TCA AGA AAC AGA TCT CAA TCT 528
Arg Ser Gly Ser Gln Ser Arg Ser Val Ser Arg Asn Arg Ser Gln Ser
165 170 175
AGA GGA AGA CAC CAT TCC AAT AAC CAG AAT AAT AAT GTT GAG GAT ACA 576
Arg Gly Arg His His Ser Asn Asn Gln Asn Asn Asn Val Glu Asp Thr
180 185 190
ATT GTA GCC GTG CTT GAA AAA TTA GGT GTT ACT GAC AAA CAA AGG TCA 624
Ile Val Ala Val Leu Glu Lys Leu Gly Val Thr Asp Lys Gln Arg Ser
195 200 205
CGT TCT AAA CCT AGA GAA CGT AGT GAT TCC AAA CCT AGG GAC ACA ACA 672
Arg Ser Lys Pro Arg Glu Arg Ser Asp Ser Lys Pro Arg Asp Thr Thr
210 215 220
CCT AAG AAT GCC AAC AAA CAC ACC TGG AAG AAA ACT GCA GGC AAG GGA 720
Pro Lys Asn Ala Asn Lys His Thr Trp Lys Lys Thr Ala Gly Lys Gly
225 230 235 240
GAT GTG ACA ACT TTC TAT GGT GCT AGA AGT AGT TCA GCT AAC TTT GGT 768
Asp Val Thr Thr Phe Tyr Gly Ala Arg Ser Ser Ser Ala Asn Phe Gly
245 250 255
GAT AGT GAT CTC GTT GCC AAT GGT AAC GCT GCC AAA TGC TAC CCT CAG 816
Asp Ser Asp Leu Val Ala Asn Gly Asn Ala Ala Lys Cys Tyr Pro Gln
260 265 270
ATA GCT GAA TGT GTT CCA TCA GTG TCT AGC ATA ATC TTT GGC AGT CAA 864
Ile Ala Glu Cys Val Pro Ser Val Ser Ser Ile Ile Phe Gly Ser Gln
275 280 285
TGG TCT GCT GAA GAA GCT GGT GAT CAA GTG AAA GTC ACG CTC ACT CAC 912
Trp Ser Ala Glu Glu Ala Gly Asp Gln Val Lys Val Thr Leu Thr His
290 295 300
ACC TAC TAC CTG CCA AAG GAT GAT GCC AAA ACT AGT CAA TTC CTA GAA 960
Thr Tyr Tyr Leu Pro Lys Asp Asp Ala Lys Thr Ser Gln Phe Leu Glu
305 310 315 320
CAG ATT GAC GCT TAC AAG CGA CCT TCT GAA GTG GCT AAG GAT CAG AGG 1008
Gln Ile Asp Ala Tyr Lys Arg Pro Ser Glu Val Ala Lys Asp Gln Arg
325 330 335
CAA AGA AGA TCC CGT TCT AAG TCT GCT GAT AAG AAG CCT GAG GAG TTG 1056
Gln Arg Arg Ser Arg Ser Lys Ser Ala Asp Lys Lys Pro Glu Glu Leu
340 345 350
TCT GTA ACT CTT GTG GAG GCA TAC ACA GAT GTG TTT GAT GAC ACA CAG 1104
Ser Val Thr Leu Val Glu Ala Tyr Thr Asp Val Phe Asp Asp Thr Gln
355 360 365
GTT GAG ATG ATT GAT GAG GTT ACG AAC TAA 1134
Val Glu Met Ile Asp Glu Val Thr Asn
370 375
配列の長さ:8710
配列の型:核酸
鎖の数:二本鎖
トポロジー:環状
配列の種類:Genomic DNA
起源
生物名:ネコ伝染性腹膜炎ウイルス
直接の起源
クローン名:pSC11-FIPV E1
配列:
CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT 60
TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC 120
TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA 180
TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT 240
GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT 300
GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC 360
CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA 420
TGTGGCGCGG TATTATCCCG TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC 480
TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC 540
ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC 600
TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG 660
GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC 720
GAGCGTGACA CCACGATGCC TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC 780
GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT 840
GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA 900
GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC 960
CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG 1020
ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA 1080
TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC 1140
CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA 1200
GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC 1260
TGCTTGCAAA CAAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA 1320
CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTCCTT 1380
CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC 1440
GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG 1500
TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG 1560
TGCACACAGC CCAGCTTGGA GCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG 1620
CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC 1680
AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT 1740
AGTCCTGTCG GGTTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG 1800
GGGCGGAGCC TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC 1860
TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT 1920
ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG CAGCGAGTCA 1980
GTGAGCGAGG AAGCGGAAGA GCGCCCAATA CGCAAACCGC CTCTCCCCGC GCGTTGGCCG 2040
ATTCATTAAT GCAGCTGGCA CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC 2100
GCAATTAATG TGAGTTAGCT CACTCATTAG GCACCCCAGG CTTTACACTT TATGCTTCCG 2160
GCTCGTATGT TGTGTGGAAT TGTGAGCGGA TAACAATTTC ACACAGGAAA CAGCTATGAC 2220
CATGATTACG CCAAGCTTTT GCGATCAATA AATGGATCAC AACCAGTATC TCTTAACGAT 2280
GTTCTTCGCA GATGATGATT CATTTTTTAA GTATTTGGCT AGTCAAGATG ATGAAATCTT 2340
CATTATCTGA TATATTGCAA ATCACTCAAT ATCTAGACTT TCTGTTATTA TTATTGATCC 2400
AATCAAAAAA TAAATTAGAA GCCGTGGGTC ATTGTTATGA ATCTCTTTCA GAGGAATACA 2460
GACAATTGAC AAAATTCACA GACTTTCAAG ATTTTAAAAA ACTGTTTAAC AAGGTCCCTA 2520
TTGTTACAGA TGGAAGGGTC AAACTTAATA AAGGATATTT GTTCGACTTT GTGATTAGTT 2580
TGATGCGATT CAAAAAAGAA TCCTCTCTAG CTACCACCGC AATAGATCCT GTTAGATACA 2640
TAGATCCTCG TCGCAATATC GCATTTTCTA ACGTGATGGA TATATTAAAG TCGAATAAAG 2700
TGAACAATAA TTAATTCTTT ATTGTCATCA TGAACGGCGG ACATATTCAG TTGATAATCG 2760
GCCCCATGTT TTCAGGTAAA AGTACAGAAT TAATTAGACG AGTTAGACGT TATCAAATAG 2820
CTCAATATAA ATGCGTGACT ATAAAATATT CTAACGATAA TAGATACGGA ACGGGACTAT 2880
GGACGCATGA TAAGAATAAT TTTGAAGCAT TGGAAGCAAC TAAACTATGT GATCTCTTGG 2940
AATCAATTAC AGATTTCTCC GTGATAGGTA TCGATGAAGG ACAGTTCTTT CCAGACATTG 3000
TTGAATTCCG AGCTTGGCTG CAGGTCGGGG ATCCCCCCTG CCCGGTTATT ATTATTTTTG 3060
ACACCAGACC AACTGGTAAT GGTAGCGAAC GGCGCTCAGC TGAATTCCGC CGATACTGAC 3120
GGGCTCCAGG AGTCGTCGCC ACCAATCCCC ATATGGAAAC CGTCGATATT CAGCCATGTG 3180
CCTTCTTCCG CGTGCAGCAG ATGGCGATGG CTGGTTTCCA TCAGTTGCTG TTGACTGTAG 3240
CGGCTGATGT TGAACTGGAA GTCGCCGCGC CACTGGTGTG GGCCATAATT CAATTCGCGC 3300
GTCCCGCAGC GCAGACCGTT TTCGCTCGGG AAGACGTACG GGGTATACAT GTCTGACAAT 3360
GGCAGATCCC AGCGGTCAAA ACAGGCGGCA GTAAGGCGGT CGGGATAGTT TTCTTGCGGC 3420
CCTAATCCGA GCCAGTTTAC CCGCTCTGCT ACCTGCGCCA GCTGGCAGTT CAGGCCAATC 3480
CGCGCCGGAT GCGGTGTATC GCTCGCCACT TCAACATCAA CGGTAATCGC CATTTGACCA 3540
CTACCATCAA TCCGGTAGGT TTTCCGGCTG ATAAATAAGG TTTTCCCCTG ATGCTGCCAC 3600
GCGTGACCGG TCGTAATCAG CACCGCATCA GCAAGTGTAT CTGCCGTGCA CTGCAACAAC 3660
GCTGCTTCGG CCTGGTAATG GCCCGCCGCC TTCCAGCGTT CGACCCAGGC GTTAGGGTCA 3720
ATGCGGGTCG CTTCACTTAC GCCAATGTCG TTATCCAGCG GTGCACGGGT GAACTGATCG 3780
CGCAGCGGCG TCAGCAGTTG TTTTTTATCG CCAATCCACA TCTGTGAAAG AAAGCCTGAC 3840
TGGCGGTTAA ATTGCCAACG CTTATTACCC AGCTCGATGC AAAAATCCAT TTCGCTGGTG 3900
GTCAGATGCG GGATGGCGTG GGACGCGGCG GGGAGCGTCA CACTGAGGTT TTCCGCCAGA 3960
CGCCACTGCT GCCAGGCGCT GATGTGCCCG GCTTCTGACC ATGCGGTCGC GTTCGGTTGC 4020
ACTACGCGTA CTGTGAGCCA GAGTTGCCCG GCGCTCTCCG GCTGCGGTAG TTCAGGCAGT 4080
TCAATCAACT GTTTACCTTG TGGAGCGACA TCCAGAGGCA CTTCACCGCT TGCCAGCGGC 4140
TTACCATCCA GCGCCACCAT CCAGTGCAGG AGCTCGTTAT CGCTATGACG GAACAGGTAT 4200
TCGCTGGTCA CTTCGATGGT TTGCCCGGAT AAACGGAACT GGAAAAACTG CTGCTGGTGT 4260
TTTGCTTCCG TCAGCGCTGG ATGCGGCGTG CGGTCGGCAA AGACCAGACC GTTCATACAG 4320
AACTGGCGAT CGTTCGGCGT ATCGCCAAAA TCACCGCCGT AAGCCGACCA CGGGTTGCCG 4380
TTTTCATCAT ATTTAATCAG CGACTGATCC ACCCAGTCCC AGACGAAGCC GCCCTGTAAA 4440
CGGGGATACT GACGAAACGC CTGCCAGTAT TTAGCGAAAC CGCCAAGACT GTTACCCATC 4500
GCGTGGGCGT ATTCGCAAAG GATCAGCGGG CGCGTCTCTC CAGGTAGCGA AAGCCATTTT 4560
TTGATGGACC ATTTCGGCAC AGCCGGGAAG GGCTGGTCTT CATCCACGCG CGCGTACATC 4620
GGGCAAATAA TATCGGTGGC CGTGGTGTCG GCTCCGCCGC CTTCATACTG CACCGGGCGG 4680
GAAGGATCGA CAGATTTGAT CCAGCGATAC AGCGCGTCGT GATTAGCGCC GTGGCCTGAT 4740
TCATTCCCCA GCGACCAGAT GATCACACTC GGGTGATTAC GATCGCGCTG CACCATTCGC 4800
GTTACGCGTT CGCTCATCGC CGGTAGCCAG CGCGGATCAT CGGTCAGACG ATTGATTGGC 4860
ACCATGCCGT GGGTTTCAAT ATTGGCTTCA TCCACCACAT ACAGGCCGTA GCGGTCGCAC 4920
AGCGTGTACC ACAGCGGATG GTTCGGATAA TGCGAACAGC GCACGGCGTT AAAGTTGTTC 4980
TGCTTCATCA GCAGGATATC CTGCACCATC GTCTGCTCAT CCATGACCTG ACCATGCAGA 5040
GGATGATGCT CGTGACGGTT AACGCCTCGA ATCAGCAACG GCTTGCCGTT CAGCAGCAGC 5100
AGACCATTTT CAATCCGCAC CTCGCGGAAA CCGACATCGC AGGCTTCTGC TTCAATCAGC 5160
GTGCCGTCGG CGGTGTGCAG TTCAACCACC GCACGATAGA GATTCGGGAT TTCGGCGCTC 5220
CACAGTTTCG GGTTTTCGAC CTTGAGACGT AGTGTGACGC GATCGGCATA ACCACCACGC 5280
TCATCGATAA TTTCACCGCC GAAAGGCGCG GTGCCGCTGG CGACCTGCGT TTCACCCTGC 5340
CATAAAGAAA CTGTTACCCG TAGGTAGTCA CGCAACTCGC CGCACATCTG AACTTCAGCC 5400
TCCAGTACAG CGCGGCTGAA ATCATCATTA AAGCGAGTGG CAACATGGAA ATCGCTGATT 5460
TGTGTAGTCG GTTTATGCAG CAACGAGACG TCACGGAAAA TGCCGCTCAT CCGCCACATA 5520
TCCTGATCTT CCAGATAACT GCCGTCACTC CAACGCAGCA CCATCACCGC GAGGCGGTTT 5580
TCTCCGGCGC GTAAAAATGC GCTCAGGTCA AATTCAGACG GCAAACGACT GTCCTGGCCG 5640
TAACCGACCC AGCGCCCGTT GCACCACAGA TGAAACGCCG AGTTAACGCC ATCAAAAATA 5700
ATTCGCGTCT GGCCTTCCTG TAGCCAGCTT TCATCAACAT TAAATGTGAG CGAGTAACAA 5760
CCCGTCGGAT TCTCCGTGGG AACAAACGGC GGATTGACCG TAATGGGATA GGTTACGTTG 5820
GTGTAGATGG GCGCATCGTA ACCGTGCATC TGCCAGTTTG AGGGGACGAC GACAGTATCG 5880
GCCTCAGGAA GATCGCACTC CAGCCAGCTT TCCGGCACCG CTTCTGGTGC CGGAAACCAG 5940
GCAAAGCGCC ATTCGCCATT CAGGCTGCGC AACTGTTGGG AAGGGCGATC GGTGCGGGCC 6000
TCTTCGCTAT TACGCCAGCT GGCGAAAGGG GGATGTGCTG CAAGGCGATT AAGTTGGGTA 6060
ACGCCAGGGT TTTCCCAGTC ACGACGTTGT AAAACGACGG GATCCCTCGA GGAATTCATT 6120
TATAGCATAG AAAAAAACAA AATGAAATTC TACTATATTT TTACATACAT ATATTCTAAA 6180
TATGAAAGTG GTGATTGTGA CTAGCGTAGC ATCGCTTCTA GACATATACT ATATAGTAAT 6240
ACCAATACTC AAGACTACGA AACTGATACA ATCTCTTATC ATGTGGGTAA TGTTCTCGAT 6300
GTCGAATAGC CATATGCCGG TAGTTGCGAT ATACATAAAC TGATCACTAA TTCCAAACCC 6360
ACCCGCTTTT TATAGTAAGT TTTTCACCCA TAAATAATAA ATACAATAAT TAATTTCTCG 6420
TAAAAGTAGA AAATATATTC TAATTTATTG CACGGTAAGG AAGTAGAATC ATAAAGAACA 6480
GTGACGGATC CCAATTCGGG CATTTTTGGT TTGAACTAAA CAAAATGAAG TACATTTTGC 6540
TAATACTCGC GTGCATAATT GCATGCGTTT ATGGTGAACG CTACTGTGCC ATGCAAGACA 6600
GTGGCTTGCA GTGTATTAAT GGCACAAATT CAAGATGTCA AACCTGCTTT GAACGTGGTG 6660
ATCTTATTTG GCATCTTGCT AACTGGAACT TCAGCTGGTC TGTAATATTG ATTGTTTTTA 6720
TAACAGTGTT ACAATATGGC AGACCACAAT TTAGCTGGCT CGTTTATGGC ATTAAAATGC 6780
TGATCATGTG GCTATTATGG CCTATTGTTC TAGCGCTTAC GATTTTTAAT GCATACTCTG 6840
AGTACCAAGT TTCCAGATAT GTAATGTTCG GCTTTAGTGT TGCAGGTGCA GTTGTAACGT 6900
TTGCACTTTG GATGATGTAT TTTGTGAGAT CTGTTCAGCT ATATAGAAGA ACCAAATCAT 6960
GGTGGTCTTT TAATCCTGAG ACTAATGCAA TTCTTTGTGT TAATGCATTG GGTAGAAGTT 7020
ATGTGCTTCC CTTAGATGGT ACTCCTACAG GTGTTACCCT TACTCTACTT TCAGGAAATC 7080
TATATGCTGA AGGTTTCAAA ATGGCTGGTG GTTTAACCAT CGAGCATTTG CCTAAATACG 7140
TCATGATTGC TACACCTAGT AGAACCATCG TTTATACATT AGTTGGAAAA CAATTAAAAG 7200
CAACTACTGC CACAGGATGG GCTTACTACG TAAAATCTAA AGCTGGTGAT TACTCAACAG 7260
AAGCACGTAC TGACAATTTG AGTGAACATG AAAAATTATT ACATATGGTG TAACTAAACT 7320
TTCAAATGGG GGAATTCTGT GAGCGTATGG CAAACGAAGG AAAAATTAGT TATAGTAGCC 7380
GCACTCGATG GGACATTTCA ACGTAAACCG TTTAATAATA TTTTGAATCT TATTCCATTA 7440
TCTGAAATGG TGGTAAAACT AACTGCTGTG TGTATGAAAT GCTTTAAGGA GGCTTCCTTT 7500
TCTAAACGAT TGGGTGAGGA AACCGAGATA GAAATAATAG GAGGTAATGA TATGTATCAA 7560
TCGGTGTGTA GAAAGTGTTA CATCGACTCA TAATATTATA TTTTTTATCT AAAAAACTAA 7620
AAATAAACAT TGATTAAATT TTAATATAAT ACTTAAAAAT GGATGTTGTG TCGTTAGATA 7680
AACCGTTTAT GTATTTTGAG GAAATTGATA ATGAGTTAGA TTACGAACCA GAAAGTGCAA 7740
ATGAGGTCGC AAAAAAACTG CCGTATCAAG GACAGTTAAA ACTATTACTA GGAGAATTAT 7800
TTTTTCTTAG TAAGTTACAG CGACACGGTA TATTAGATGG TGCCACCGTA GTGTATATAG 7860
GATCTGCTCC CGGTACACAT ATACGTTATT TGAGAGATCA TTTCTATAAT TTAGGAGTGA 7920
TCATCAAATG GATGCTAATT GACGGCCGCC ATCATGATCC TATTTTAAAT GGATTGCGTG 7980
ATGTGACTCT AGTGACTCGG TTCGTTGATG AGGAATATCT ACGATCCATC AAAAAACAAC 8040
TGCATCCTTC TAAGATTATT TTAATTTCTG ATGTGAGATC CAAACGAGGA GGAAATGAAC 8100
CTAGTACGGC GGATTTACTA AGTAATTACG CTCTACAAAA TGTCATGATT AGTATTTTAA 8160
ACCCCGTGGC GTCTAGTCTT AAATGGAGAT GCCCGTTTCC AGATCAATGG ATCAAGGACT 8220
TTTATATCCC ACACGGTAAT AAAATGTTAC AACCTTTTGC TCCTTCATAT TCAGGGCCGT 8280
CGTTTTACAA CGTCGTGACT GGGAAAACCC TGGCGTTACC CAACTTAATC GCCTTGCAGC 8340
ACATCCCCCT TTCGCCAGCT GGCGTAATAG CGAAGAGGCC CGCACCGATC GCCCTTCCCA 8400
ACAGTTGCGC AGCCTGAATG GCGAATGGCG CCTGATGCGG TATTTTCTCT TTACGCATCT 8460
GTGCGGTATT TCACACCGCA TATGGTGCAC TCTCAGTACC ATCTGCTCTG ATGCCGCATA 8520
GTTAAGCCAG TACACTCCGC TATCGCTACG TGACTGGGTC ATGGCTGCGC CCCGACACCC 8580
GCCAACACCC GCTGACGCGC CCTGACGGGC TTGTCTGCTC CCGGCATCCG CTTACAGACA 8640
AGCTGTGACC GTCTCCGGGA GCTGCATGTG TCAGAGGTTT TCACCGTCAT CACCGAAACG 8700
CGCGAGGCAG 8710
配列の長さ:9019
配列の型:核酸
鎖の数:二本鎖
トポロジー:環状
配列の種類:Genomic DNA
起源
生物名:ネコ免疫不全ウイルス
直接の起源
クローン名:pSC11-FIPV N
配列:
CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT 60
TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC 120
TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA 180
TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT 240
GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT 300
GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC 360
CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA 420
TGTGGCGCGG TATTATCCCG TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC 480
TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC 540
ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC 600
TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG 660
GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC 720
GAGCGTGACA CCACGATGCC TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC 780
GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT 840
GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA 900
GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC 960
CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG 1020
ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA 1080
TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC 1140
CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA 1200
GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC 1260
TGCTTGCAAA CAAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA 1320
CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTCCTT 1380
CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC 1440
GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG 1500
TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG 1560
TGCACACAGC CCAGCTTGGA GCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG 1620
CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC 1680
AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT 1740
AGTCCTGTCG GGTTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG 1800
GGGCGGAGCC TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC 1860
TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT 1920
ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG CAGCGAGTCA 1980
GTGAGCGAGG AAGCGGAAGA GCGCCCAATA CGCAAACCGC CTCTCCCCGC GCGTTGGCCG 2040
ATTCATTAAT GCAGCTGGCA CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC 2100
GCAATTAATG TGAGTTAGCT CACTCATTAG GCACCCCAGG CTTTACACTT TATGCTTCCG 2160
GCTCGTATGT TGTGTGGAAT TGTGAGCGGA TAACAATTTC ACACAGGAAA CAGCTATGAC 2220
CATGATTACG CCAAGCTTTT GCGATCAATA AATGGATCAC AACCAGTATC TCTTAACGAT 2280
GTTCTTCGCA GATGATGATT CATTTTTTAA GTATTTGGCT AGTCAAGATG ATGAAATCTT 2340
CATTATCTGA TATATTGCAA ATCACTCAAT ATCTAGACTT TCTGTTATTA TTATTGATCC 2400
AATCAAAAAA TAAATTAGAA GCCGTGGGTC ATTGTTATGA ATCTCTTTCA GAGGAATACA 2460
GACAATTGAC AAAATTCACA GACTTTCAAG ATTTTAAAAA ACTGTTTAAC AAGGTCCCTA 2520
TTGTTACAGA TGGAAGGGTC AAACTTAATA AAGGATATTT GTTCGACTTT GTGATTAGTT 2580
TGATGCGATT CAAAAAAGAA TCCTCTCTAG CTACCACCGC AATAGATCCT GTTAGATACA 2640
TAGATCCTCG TCGCAATATC GCATTTTCTA ACGTGATGGA TATATTAAAG TCGAATAAAG 2700
TGAACAATAA TTAATTCTTT ATTGTCATCA TGAACGGCGG ACATATTCAG TTGATAATCG 2760
GCCCCATGTT TTCAGGTAAA AGTACAGAAT TAATTAGACG AGTTAGACGT TATCAAATAG 2820
CTCAATATAA ATGCGTGACT ATAAAATATT CTAACGATAA TAGATACGGA ACGGGACTAT 2880
GGACGCATGA TAAGAATAAT TTTGAAGCAT TGGAAGCAAC TAAACTATGT GATCTCTTGG 2940
AATCAATTAC AGATTTCTCC GTGATAGGTA TCGATGAAGG ACAGTTCTTT CCAGACATTG 3000
TTGAATTCCG AGCTTGGCTG CAGGTCGGGG ATCCCCCCTG CCCGGTTATT ATTATTTTTG 3060
ACACCAGACC AACTGGTAAT GGTAGCGAAC GGCGCTCAGC TGAATTCCGC CGATACTGAC 3120
GGGCTCCAGG AGTCGTCGCC ACCAATCCCC ATATGGAAAC CGTCGATATT CAGCCATGTG 3180
CCTTCTTCCG CGTGCAGCAG ATGGCGATGG CTGGTTTCCA TCAGTTGCTG TTGACTGTAG 3240
CGGCTGATGT TGAACTGGAA GTCGCCGCGC CACTGGTGTG GGCCATAATT CAATTCGCGC 3300
GTCCCGCAGC GCAGACCGTT TTCGCTCGGG AAGACGTACG GGGTATACAT GTCTGACAAT 3360
GGCAGATCCC AGCGGTCAAA ACAGGCGGCA GTAAGGCGGT CGGGATAGTT TTCTTGCGGC 3420
CCTAATCCGA GCCAGTTTAC CCGCTCTGCT ACCTGCGCCA GCTGGCAGTT CAGGCCAATC 3480
CGCGCCGGAT GCGGTGTATC GCTCGCCACT TCAACATCAA CGGTAATCGC CATTTGACCA 3540
CTACCATCAA TCCGGTAGGT TTTCCGGCTG ATAAATAAGG TTTTCCCCTG ATGCTGCCAC 3600
GCGTGACCGG TCGTAATCAG CACCGCATCA GCAAGTGTAT CTGCCGTGCA CTGCAACAAC 3660
GCTGCTTCGG CCTGGTAATG GCCCGCCGCC TTCCAGCGTT CGACCCAGGC GTTAGGGTCA 3720
ATGCGGGTCG CTTCACTTAC GCCAATGTCG TTATCCAGCG GTGCACGGGT GAACTGATCG 3780
CGCAGCGGCG TCAGCAGTTG TTTTTTATCG CCAATCCACA TCTGTGAAAG AAAGCCTGAC 3840
TGGCGGTTAA ATTGCCAACG CTTATTACCC AGCTCGATGC AAAAATCCAT TTCGCTGGTG 3900
GTCAGATGCG GGATGGCGTG GGACGCGGCG GGGAGCGTCA CACTGAGGTT TTCCGCCAGA 3960
CGCCACTGCT GCCAGGCGCT GATGTGCCCG GCTTCTGACC ATGCGGTCGC GTTCGGTTGC 4020
ACTACGCGTA CTGTGAGCCA GAGTTGCCCG GCGCTCTCCG GCTGCGGTAG TTCAGGCAGT 4080
TCAATCAACT GTTTACCTTG TGGAGCGACA TCCAGAGGCA CTTCACCGCT TGCCAGCGGC 4140
TTACCATCCA GCGCCACCAT CCAGTGCAGG AGCTCGTTAT CGCTATGACG GAACAGGTAT 4200
TCGCTGGTCA CTTCGATGGT TTGCCCGGAT AAACGGAACT GGAAAAACTG CTGCTGGTGT 4260
TTTGCTTCCG TCAGCGCTGG ATGCGGCGTG CGGTCGGCAA AGACCAGACC GTTCATACAG 4320
AACTGGCGAT CGTTCGGCGT ATCGCCAAAA TCACCGCCGT AAGCCGACCA CGGGTTGCCG 4380
TTTTCATCAT ATTTAATCAG CGACTGATCC ACCCAGTCCC AGACGAAGCC GCCCTGTAAA 4440
CGGGGATACT GACGAAACGC CTGCCAGTAT TTAGCGAAAC CGCCAAGACT GTTACCCATC 4500
GCGTGGGCGT ATTCGCAAAG GATCAGCGGG CGCGTCTCTC CAGGTAGCGA AAGCCATTTT 4560
TTGATGGACC ATTTCGGCAC AGCCGGGAAG GGCTGGTCTT CATCCACGCG CGCGTACATC 4620
GGGCAAATAA TATCGGTGGC CGTGGTGTCG GCTCCGCCGC CTTCATACTG CACCGGGCGG 4680
GAAGGATCGA CAGATTTGAT CCAGCGATAC AGCGCGTCGT GATTAGCGCC GTGGCCTGAT 4740
TCATTCCCCA GCGACCAGAT GATCACACTC GGGTGATTAC GATCGCGCTG CACCATTCGC 4800
GTTACGCGTT CGCTCATCGC CGGTAGCCAG CGCGGATCAT CGGTCAGACG ATTGATTGGC 4860
ACCATGCCGT GGGTTTCAAT ATTGGCTTCA TCCACCACAT ACAGGCCGTA GCGGTCGCAC 4920
AGCGTGTACC ACAGCGGATG GTTCGGATAA TGCGAACAGC GCACGGCGTT AAAGTTGTTC 4980
TGCTTCATCA GCAGGATATC CTGCACCATC GTCTGCTCAT CCATGACCTG ACCATGCAGA 5040
GGATGATGCT CGTGACGGTT AACGCCTCGA ATCAGCAACG GCTTGCCGTT CAGCAGCAGC 5100
AGACCATTTT CAATCCGCAC CTCGCGGAAA CCGACATCGC AGGCTTCTGC TTCAATCAGC 5160
GTGCCGTCGG CGGTGTGCAG TTCAACCACC GCACGATAGA GATTCGGGAT TTCGGCGCTC 5220
CACAGTTTCG GGTTTTCGAC CTTGAGACGT AGTGTGACGC GATCGGCATA ACCACCACGC 5280
TCATCGATAA TTTCACCGCC GAAAGGCGCG GTGCCGCTGG CGACCTGCGT TTCACCCTGC 5340
CATAAAGAAA CTGTTACCCG TAGGTAGTCA CGCAACTCGC CGCACATCTG AACTTCAGCC 5400
TCCAGTACAG CGCGGCTGAA ATCATCATTA AAGCGAGTGG CAACATGGAA ATCGCTGATT 5460
TGTGTAGTCG GTTTATGCAG CAACGAGACG TCACGGAAAA TGCCGCTCAT CCGCCACATA 5520
TCCTGATCTT CCAGATAACT GCCGTCACTC CAACGCAGCA CCATCACCGC GAGGCGGTTT 5580
TCTCCGGCGC GTAAAAATGC GCTCAGGTCA AATTCAGACG GCAAACGACT GTCCTGGCCG 5640
TAACCGACCC AGCGCCCGTT GCACCACAGA TGAAACGCCG AGTTAACGCC ATCAAAAATA 5700
ATTCGCGTCT GGCCTTCCTG TAGCCAGCTT TCATCAACAT TAAATGTGAG CGAGTAACAA 5760
CCCGTCGGAT TCTCCGTGGG AACAAACGGC GGATTGACCG TAATGGGATA GGTTACGTTG 5820
GTGTAGATGG GCGCATCGTA ACCGTGCATC TGCCAGTTTG AGGGGACGAC GACAGTATCG 5880
GCCTCAGGAA GATCGCACTC CAGCCAGCTT TCCGGCACCG CTTCTGGTGC CGGAAACCAG 5940
GCAAAGCGCC ATTCGCCATT CAGGCTGCGC AACTGTTGGG AAGGGCGATC GGTGCGGGCC 6000
TCTTCGCTAT TACGCCAGCT GGCGAAAGGG GGATGTGCTG CAAGGCGATT AAGTTGGGTA 6060
ACGCCAGGGT TTTCCCAGTC ACGACGTTGT AAAACGACGG GATCCCTCGA GGAATTCATT 6120
TATAGCATAG AAAAAAACAA AATGAAATTC TACTATATTT TTACATACAT ATATTCTAAA 6180
TATGAAAGTG GTGATTGTGA CTAGCGTAGC ATCGCTTCTA GACATATACT ATATAGTAAT 6240
ACCAATACTC AAGACTACGA AACTGATACA ATCTCTTATC ATGTGGGTAA TGTTCTCGAT 6300
GTCGAATAGC CATATGCCGG TAGTTGCGAT ATACATAAAC TGATCACTAA TTCCAAACCC 6360
ACCCGCTTTT TATAGTAAGT TTTTCACCCA TAAATAATAA ATACAATAAT TAATTTCTCG 6420
TAAAAGTAGA AAATATATTC TAATTTATTG CACGGTAAGG AAGTAGAATC ATAAAGAACA 6480
GTGACGGATC CCGGGATGGC CACACAGGGA CAACGCGTCA ACTGGGGAGA TGAACCTTCC 6540
AAAAGACGTG GTCGTTCTAA CTCTCGTGGT CGGAAGAATA ATGATATACC TTTGTCATTC 6600
TACAACCCCA TTACCCTCGA ACAAGGATCT AAATTTTGGA ATTTATGTCC GAGAGACCTT 6660
GTTCCCAAAG GAATAGGTAA TAAGGATCAA CAAATTGGTT ATTGGAATAG ACAGATTCGT 6720
TATCGTATTG TAAAAGGCCA GCGTAAGGAA CTCGCTGAGA GGTGGTTCTT TTACTTCTTA 6780
GGTACAGGAC CTCATGCTGA TGCTAAATTC AAAGACAAGA TTGATGGAGT CTTCTGGGTT 6840
GCAAGGGATG GTGCCATGAA CAAGCCCACA ACGCTTGGCA CTCGTGGAAC CAATAACGAA 6900
TCCAAACCAC TGAGATTTGA TGGTAAGATA CCGCCACAGT TTCAGCTTGA AGTGAACCGT 6960
TCTAGGAACA ATTCAAGGTC TGGTTCTCAG TCTAGATCTG TTTCAAGAAA CAGATCTCAA 7020
TCTAGAGGAA GACACCATTC CAATAACCAG AATAATAATG TTGAGGATAC AATTGTAGCC 7080
GTGCTTGAAA AATTAGGTGT TACTGACAAA CAAAGGTCAC GTTCTAAACC TAGAGAACGT 7140
AGTGATTCCA AACCTAGGGA CACAACACCT AAGAATGCCA ACAAACACAC CTGGAAGAAA 7200
ACTGCAGGCA AGGGAGATGT GACAACTTTC TATGGTGCTA GAAGTAGTTC AGCTAACTTT 7260
GGTGATAGTG ATCTCGTTGC CAATGGTAAC GCTGCCAAAT GCTACCCTCA GATAGCTGAA 7320
TGTGTTCCAT CAGTGTCTAG CATAATCTTT GGCAGTCAAT GGTCTGCTGA AGAAGCTGGT 7380
GATCAAGTGA AAGTCACGCT CACTCACACC TACTACCTGC CAAAGGATGA TGCCAAAACT 7440
AGTCAATTCC TAGAACAGAT TGACGCTTAC AAGCGACCTT CTGAAGTGGC TAAGGATCAG 7500
AGGCAAAGAA GATCCCGTTC TAAGTCTGCT GATAAGAAGC CTGAGGAGTT GTCTGTAACT 7560
CTTGTGGAGG CATACACAGA TGTGTTTGAT GACACACAGG TTGAGATGAT TGATGAGGTT 7620
ACGAACTAAA CGCATGCCCG GGAATTCTGT GAGCGTATGG CAAACGAAGG AAAAATTAGT 7680
TATAGTAGCC GCACTCGATG GGACATTTCA ACGTAAACCG TTTAATAATA TTTTGAATCT 7740
TATTCCATTA TCTGAAATGG TGGTAAAACT AACTGCTGTG TGTATGAAAT GCTTTAAGGA 7800
GGCTTCCTTT TCTAAACGAT TGGGTGAGGA AACCGAGATA GAAATAATAG GAGGTAATGA 7860
TATGTATCAA TCGGTGTGTA GAAAGTGTTA CATCGACTCA TAATATTATA TTTTTTATCT 7920
AAAAAACTAA AAATAAACAT TGATTAAATT TTAATATAAT ACTTAAAAAT GGATGTTGTG 7980
TCGTTAGATA AACCGTTTAT GTATTTTGAG GAAATTGATA ATGAGTTAGA TTACGAACCA 8040
GAAAGTGCAA ATGAGGTCGC AAAAAAACTG CCGTATCAAG GACAGTTAAA ACTATTACTA 8100
GGAGAATTAT TTTTTCTTAG TAAGTTACAG CGACACGGTA TATTAGATGG TGCCACCGTA 8160
GTGTATATAG GATCTGCTCC CGGTACACAT ATACGTTATT TGAGAGATCA TTTCTATAAT 8220
TTAGGAGTGA TCATCAAATG GATGCTAATT GACGGCCGCC ATCATGATCC TATTTTAAAT 8280
GGATTGCGTG ATGTGACTCT AGTGACTCGG TTCGTTGATG AGGAATATCT ACGATCCATC 8340
AAAAAACAAC TGCATCCTTC TAAGATTATT TTAATTTCTG ATGTGAGATC CAAACGAGGA 8400
GGAAATGAAC CTAGTACGGC GGATTTACTA AGTAATTACG CTCTACAAAA TGTCATGATT 8460
AGTATTTTAA ACCCCGTGGC GTCTAGTCTT AAATGGAGAT GCCCGTTTCC AGATCAATGG 8520
ATCAAGGACT TTTATATCCC ACACGGTAAT AAAATGTTAC AACCTTTTGC TCCTTCATAT 8580
TCAGGGCCGT CGTTTTACAA CGTCGTGACT GGGAAAACCC TGGCGTTACC CAACTTAATC 8640
GCCTTGCAGC ACATCCCCCT TTCGCCAGCT GGCGTAATAG CGAAGAGGCC CGCACCGATC 8700
GCCCTTCCCA ACAGTTGCGC AGCCTGAATG GCGAATGGCG CCTGATGCGG TATTTTCTCT 8760
TTACGCATCT GTGCGGTATT TCACACCGCA TATGGTGCAC TCTCAGTACC ATCTGCTCTG 8820
ATGCCGCATA GTTAAGCCAG TACACTCCGC TATCGCTACG TGACTGGGTC ATGGCTGCGC 8880
CCCGACACCC GCCAACACCC GCTGACGCGC CCTGACGGGC TTGTCTGCTC CCGGCATCCG 8940
CTTACAGACA AGCTGTGACC GTCTCCGGGA GCTGCATGTG TCAGAGGTTT TCACCGTCAT 9000
CACCGAAACG CGCGAGGCAG 9020
Claims (9)
- ネコ伝染性腹膜炎ウイルス(FIPV)のヌクレオカプシド(N)およびトランスメンブレン(M/E1)タンパクからなる群から選択される要素をコードするDNA配列からなる少なくとも1つの内部遺伝子を有する組換えアライグマポックスウイルスと、医薬上許容される担体または希釈剤と、医薬上許容されるアジュバントとからなることを特徴とするワクチン;ただし、当該内部遺伝子がFIPVのNタンパクをコードするDNA配列だけを含むものを除く。
- 前記内部遺伝子が配列表の配列番号:1に示すアミノ酸配列を有するFIPVのM/E1タンパクをコードする請求項1記載のワクチン。
- 前記ウイルスがFIPVのE1およびNタンパクをコードする遺伝子を有する請求項1記載のワクチン。
- ネコ白血病ウイルス、ネコ汎白血球減少症、ネコ鼻気管炎ウイルス、ネコカリチウイルス、ネコ免疫不全ウイルス、ネコヘルペスウイルス、ネコ腸内コロナウイルス、またはこれらの組合せからなる群から選択される不活性化または弱毒化されたウイルスをさらに含有する請求項1記載のワクチン。
- 不活性化または弱毒化されたネコオオム病クラミジア(Chlamydia psittaci)、イヌ小胞子菌(Microsporum canis)、またはこれらの組合せをさらに含有する請求項1記載のワクチン。
- ネコ伝染性腹膜炎ウイルス(FIPV)のヌクレオカプシド(N)およびトランスメンブレン(M/E1)タンパクからなる群から選択される要素をコードするDNA配列からなる少なくとも1つの内部遺伝子を有する第1の組換えアライグマポックスウイルスと、ネコ伝染性腹膜炎ウイルス(FIPV)のヌクレオカプシド(N)およびトランスメンブレン(M/E1)タンパクからなる群から選択される要素をコードするDNA配列からなる少なくとも1つの内部遺伝子を有する第2の組換えアライグマポックスウイルスと、医薬上許容される担体または希釈剤と、医薬上許容されるアジュバントとからなることを特徴とするワクチン;ただし、当該内部遺伝子がFIPVのNタンパクをコードするDNA配列だけを含むものを除く。
- ネコ伝染性腹膜炎ウイルス(FIPV)に起因する疾患を予防する方法であって、このような処置を必要とするネコに、ネコ伝染性腹膜炎ウイルス(FIPV)のヌクレオカプシド(N)およびトランスメンブレン(M/E1)タンパクからなる群から選択される要素をコードするDNA配列からなる少なくとも1つの内部遺伝子を有する組換えアライグマポックスウイルスを含有するワクチンを投与することを特徴とする方法;ただし、当該内部遺伝子がFIPVのNタンパクをコードするDNA配列だけを含むものを除く。
- 前記内部遺伝子が配列表の配列番号:1に示すアミノ酸配列を有するFIPVのM/E1タンパクをコードする請求項7記載の方法。
- 前記ウイルスがFIPVのE1およびNタンパクをコードする遺伝子を有する請求項7記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12551693A | 1993-09-22 | 1993-09-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6223293A Division JPH07184662A (ja) | 1993-09-22 | 1994-09-19 | 組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005336206A true JP2005336206A (ja) | 2005-12-08 |
Family
ID=22420074
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6223293A Ceased JPH07184662A (ja) | 1993-09-22 | 1994-09-19 | 組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 |
JP2005232394A Pending JP2005336206A (ja) | 1993-09-22 | 2005-08-10 | 組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6223293A Ceased JPH07184662A (ja) | 1993-09-22 | 1994-09-19 | 組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US5770211A (ja) |
EP (1) | EP0652287B1 (ja) |
JP (2) | JPH07184662A (ja) |
AT (1) | ATE233821T1 (ja) |
AU (1) | AU680531B2 (ja) |
CA (1) | CA2132374C (ja) |
DE (1) | DE69432207T2 (ja) |
DK (1) | DK0652287T3 (ja) |
ES (1) | ES2188605T3 (ja) |
NZ (1) | NZ264518A (ja) |
PT (1) | PT652287E (ja) |
SG (1) | SG55095A1 (ja) |
TW (1) | TW377373B (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7202225B1 (en) * | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
US20020123476A1 (en) * | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
US6241989B1 (en) * | 1991-07-09 | 2001-06-05 | Cornell Research Foundation, Inc. | Recombinant multivalent viral vaccine |
US7087234B1 (en) * | 1991-07-09 | 2006-08-08 | Cornell Research Foundation, Inc. | Recombinant multivalent viral vaccine |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
FR2751223B1 (fr) | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
AU5597998A (en) * | 1996-12-04 | 1998-06-29 | Heska Corporation | Recombinant plague vaccine |
AU7350798A (en) * | 1997-04-29 | 1998-11-24 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
US6106841A (en) * | 1998-02-04 | 2000-08-22 | Heska Corporation | Delivery method for recombinant raccoon poxvirus |
US20050161884A1 (en) * | 1998-02-17 | 2005-07-28 | Au-Yeung Chi F. | Method of and apparatus for playing a card game |
ES2367245T3 (es) * | 1998-05-01 | 2011-10-31 | Schering-Plough Ltd. | Virus recombinante que expresa adn foráneo que condifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo. |
US7279168B2 (en) | 1998-05-01 | 2007-10-09 | Texas A & M University System | Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof |
PT1370668E (pt) | 2001-03-08 | 2006-06-30 | Akzo Nobel Nv | Vacinas de vector baseadas em leporipox |
US7255986B2 (en) * | 2002-01-31 | 2007-08-14 | The Board Of Trustees Operating Michigan State University | Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets |
JP4242607B2 (ja) * | 2002-07-04 | 2009-03-25 | 学校法人北里研究所 | ネコ伝染性腹膜炎ワクチン |
WO2008150404A1 (en) * | 2007-05-30 | 2008-12-11 | Wyeth | Raccoon poxvirus expressing genes of feline antigens |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8107025A1 (es) * | 1978-11-30 | 1980-12-16 | Wellcome Found | Un metodo de preparar una vacuna que contiene una cepa ate- nuada de virus de peritonitis infecciosa felina. |
US4293653A (en) * | 1979-04-12 | 1981-10-06 | Horzinek Marian C | Method for propagating feline infectious peritonitis virus |
US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
JPS63123385A (ja) * | 1986-09-05 | 1988-05-27 | デュファル・インテルナチオナル・レセールフ・ベー・ヴェー | 新規抗原的活性蛋白質およびぺプチド、並びにネコ科感染性腹膜炎ウイルスワクチン |
US5266313A (en) * | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
IL87911A0 (en) * | 1987-10-01 | 1989-03-31 | Norden Lab Inc | Vaccine for protection of cats against feline infectious peritonitis |
CA2005291C (en) * | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
CA2011025A1 (en) * | 1989-03-01 | 1990-09-01 | Terry R. Beardsley | Feline infectious peritonitis vaccine |
HUT54733A (en) * | 1989-07-12 | 1991-03-28 | Duphar Int Res | Process for producing new, antigenically active proteins and peptides, as well as feline infectious peritonitis virus (fipv) vaccines |
US5242686A (en) * | 1990-11-07 | 1993-09-07 | American Home Products Corporation | Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
NZ240558A (en) * | 1990-11-14 | 1994-11-25 | Smithkline Beecham Corp | Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease |
WO1993001284A1 (en) * | 1991-07-09 | 1993-01-21 | Cornell Research Foundation, Inc. | Recombinant viral vaccine |
-
1994
- 1994-08-30 TW TW083107942A patent/TW377373B/zh not_active IP Right Cessation
- 1994-09-19 JP JP6223293A patent/JPH07184662A/ja not_active Ceased
- 1994-09-19 CA CA002132374A patent/CA2132374C/en not_active Expired - Fee Related
- 1994-09-21 ES ES94306917T patent/ES2188605T3/es not_active Expired - Lifetime
- 1994-09-21 DE DE69432207T patent/DE69432207T2/de not_active Expired - Fee Related
- 1994-09-21 SG SG1996005965A patent/SG55095A1/en unknown
- 1994-09-21 EP EP94306917A patent/EP0652287B1/en not_active Expired - Lifetime
- 1994-09-21 PT PT94306917T patent/PT652287E/pt unknown
- 1994-09-21 DK DK94306917T patent/DK0652287T3/da active
- 1994-09-21 AU AU74116/94A patent/AU680531B2/en not_active Ceased
- 1994-09-21 AT AT94306917T patent/ATE233821T1/de not_active IP Right Cessation
- 1994-09-22 NZ NZ264518A patent/NZ264518A/en not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/480,210 patent/US5770211A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,882 patent/US5656275A/en not_active Expired - Lifetime
-
2005
- 2005-08-10 JP JP2005232394A patent/JP2005336206A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US5770211A (en) | 1998-06-23 |
SG55095A1 (en) | 1998-12-21 |
NZ264518A (en) | 1996-06-25 |
DK0652287T3 (da) | 2003-04-07 |
ES2188605T3 (es) | 2003-07-01 |
CA2132374A1 (en) | 1995-03-23 |
ATE233821T1 (de) | 2003-03-15 |
AU680531B2 (en) | 1997-07-31 |
EP0652287A2 (en) | 1995-05-10 |
CA2132374C (en) | 2005-05-17 |
EP0652287B1 (en) | 2003-03-05 |
JPH07184662A (ja) | 1995-07-25 |
DE69432207D1 (de) | 2003-04-10 |
AU7411694A (en) | 1995-04-06 |
US5656275A (en) | 1997-08-12 |
PT652287E (pt) | 2003-06-30 |
DE69432207T2 (de) | 2003-11-13 |
EP0652287A3 (en) | 1997-06-11 |
TW377373B (en) | 1999-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005336206A (ja) | 組換えアライグマポックスウイルスおよびネコ伝染性腹膜炎ウイルス疾患に対する効果的なワクチンとしてのそれらの使用 | |
CN111705006B (zh) | 表达新型冠状病毒s蛋白的口服重组酵母及其制备与应用 | |
CN111825772B (zh) | 具有变异衣壳蛋白的腺相关病毒及其应用 | |
CN106755036B (zh) | 一种细菌和抗体结合双靶向抑杀实体瘤药物的制备方法 | |
CN108823226A (zh) | 一种中国大豆花叶病毒侵染性克隆载体及其构建方法和应用 | |
KR101961667B1 (ko) | 돼지유행성설사병 바이러스에 내성을 가지는 형질전환 복제돼지 및 이의 제조방법 | |
CN114262381B (zh) | 表面展示非洲猪瘟病毒抗原p30蛋白的重组杆状病毒、制备方法及其应用 | |
CN106591208A (zh) | 表达DNase I、AIF或整合有该毒素的重组单链抗体的载体菌株及该菌株的应用 | |
CN102719471A (zh) | 整合质粒pOPHI及无抗性筛选标记的自主发光分枝杆菌 | |
CN112501139B (zh) | 一株重组新城疫病毒毒株及其制备方法和应用 | |
CN112250738B (zh) | 严重急性呼吸综合征冠状病毒2病毒样颗粒的制备、纯化和鉴定方法 | |
CN104328136B (zh) | 鸡新城疫病毒毒株rClone30‑fliC的制备及其在鸡新城疫病防治中的应用 | |
CN114846141B (zh) | 一种分离的核酸分子及其应用 | |
PT91520A (pt) | Processo para a preparacao de proteinas por expressao de proteinas homologas e heterologas funcionais a partir da membrana exterior de e. coli e de outras bacterias gram-negativas | |
CN113736676A (zh) | 一种表达猪流行性腹泻病毒s蛋白的口服重组酿酒酵母的制备与应用 | |
CN106755105A (zh) | 一质粒拯救系统用于流感病毒疫苗株的制备及应用 | |
CN113073102B (zh) | 自噬基因atg9在水稻育种和/或水稻粒型机制研究中的应用 | |
CN108949691B (zh) | 一种制备可实时检测间充质干细胞衰老的细胞模型的方法 | |
KR20230018284A (ko) | 발현 시스템 및 이를 이용한 핵산 기반 백신 | |
CN108949690B (zh) | 一种制备可实时检测间充质干细胞骨分化的细胞模型的方法 | |
CN109321601B (zh) | Aqp5重组过表达载体及其构建方法和用途 | |
CN109082443A (zh) | 一种制备可实时检测间充质干细胞向成熟肝样细胞分化的细胞模型的方法 | |
CN109628487A (zh) | 一种利用转基因猪唾液腺制备人神经生长因子的方法 | |
CN113817621B (zh) | 同时表达IFNa14蛋白和人乙肝病毒S蛋白的重组酿酒酵母菌株及制备方法和应用 | |
CN107354172B (zh) | 重组表达载体及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060602 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060607 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070403 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080819 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080825 |